Navigation Links
Robert S. Langer, Sc.D., joins eLux Medical Scientific Advisory Board
Date:8/12/2014

SAN DIEGO, Aug. 12, 2014 /PRNewswire-iReach/ -- eLux Medical, Inc., developer of NanoLipo™, a novel nanomedicine approach to liposuction, is pleased to announce that Professor Robert S. Langer, Sc.D., has joined its Scientific Advisory Board. Dr. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has written over 1,250 articles and has over 1,060 patents worldwide, many of which have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. (a full biography for Dr. Langer is available at web.mit.edu/langerlab/langer.html.)

Dr. Langer stated: "NanoLipo is a very novel approach to making liposuction a more consistent and successful procedure for both physicians and their patients. I am very pleased to be asked to contribute to its development."

Dr. Langer will advise eLux as it prepares for the clinical trial phase of the development of NanoLipo, a proprietary injectable solution of gold nanoparticles which is projected to transform the performance and results of liposuction, the number one cosmetic surgery worldwide.

eLux co-Founder and Chief Technology Officer, Professor Adah Almutairi, Ph.D., said: "the pre-clinical results of NanoLipo have been very encouraging. As we move into clinical trials, we are honored to have Dr. Langer join our Scientific Advisory Board. His extensive experience and advice will be invaluable throughout our technical development and commercialization process."

About eLux Medical, Inc.

San Diego based eLux Medical is a development stage company, which has spun out of the University of California San Diego (UCSD) Center of Excellence in Nanomedicine, of which Professor Adah Almutairi is the Director. eLux Medical has an exclusive worldwide license on the intellectual property related to NanoLipo from UCSD.

About Forward-Looking Statements

The Company cautions you that the statements included in the press release that are not a description of historical facts are forward-looking statements. These include statements regarding the potential clinical benefits of NanoLipo and the commercial prospects of eLux Medical, Inc. NanoLipo is an investigational device and is not approved for sale in the USA or any other country.

CONTACT

John R. Lyon, CEO

760-745-0855

johnlyon@eluxmedical.com

 

MEDIA

Chris Smith

858-220-6939

info@eluxmedical.com

Media Contact: Chris Smith, eLux Medical Inc,, 858-220-6939, info@eluxmedical.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE eLux Medical Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. TB Alliance Names Elana Robertson Senior Vice President, Market Access
2. CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial Officer, Robert Kane
3. Varian Imaging Components President Robert Kluge Announces Plans to Retire; Varian CEO Dow Wilson Names Sunny Sanyal as Kluges Successor
4. Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer
5. Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
6. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
7. Medical Laser Expert Robert E. Grove, PhD Appointed To Ellman International Board of Directors
8. BioLife Solutions Announces the Addition of Robert Preti, Ph.D. to its Scientific Advisory Board
9. Dr. Robert Bernstein in NY Magazines Best Doctors Issue for 14th Consecutive Year
10. UBM Canon and MD+DI, the Global MedTech Authorities, Announce Dr. Robert Langer as the 2013 MDEA Lifetime Achievement Award Recipient
11. NxStage Names Robert G. Funari Chairman Of The Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):